Locally advanced esophageal adenocarcinoma: Current standards and molecular predictors of outcome

Harry H. Yoon, Arlene A. Forastiere

Research output: Contribution to journalReview article

4 Scopus citations


Despite decades of effort to improve outcomes, esophageal cancer remains a highly fatal disease. The optimal approach to cure is still debated globally, although a consensus favoring trimodality therapy has emerged in the USA. In this review, after providing a brief update on current standards of therapy in locally advanced esophageal cancer, we focus on one area in which the field is headed: the identification of molecular outcome markers, with the ultimate goal of individualizing therapy according to pretreatment profiles. We attempt to clarify the somewhat unwieldy body of literature in this area, with a focus on adenocarcinoma, keeping the clinician and clinical researcher particularly in mind.

Original languageEnglish (US)
Pages (from-to)413-425
Number of pages13
JournalFuture Oncology
Issue number3
StatePublished - Jun 1 2008



  • EGFR
  • Esophageal cancer
  • Gene expression profiling
  • Immunohistochemistry
  • Methylation
  • NF-κB
  • Outcome prediction
  • Proteomics
  • Single nucleotide polymorphism
  • Trimodality therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this